{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:56:34Z","timestamp":1792684594748,"version":"4.5.0"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background.<\/jats:title>\n                    <jats:p>The short-term efficacy and safety of everolimus in combination with tacrolimus have been described in several clinical trials. Yet, detailed long-term data comparing the use of everolimus or mycophenolate in kidney transplant recipients receiving tacrolimus are lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods.<\/jats:title>\n                    <jats:p>This is a 5-y follow-up post hoc analysis of a prospective trial including 288 patients who were randomized to receive a single 3-mg\/kg dose of rabbit antithymocyte globulin, tacrolimus, everolimus (EVR), and prednisone (rabbit antithymocyte globulin\/EVR, n\u2009=\u200985); basiliximab, tacrolimus, everolimus, and prednisone (basiliximab\/EVR, n\u2009=\u2009102); or basiliximab, tacrolimus, mycophenolate, and prednisone (basiliximab\/mycophenolate, n\u2009=\u2009101).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.<\/jats:title>\n                    <jats:p>\n                      There were no differences in the incidence of treatment failure (31.8% versus 40.2% versus 34.7%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.468), de novo donor-specific HLA antibodies (6.5% versus 11.7% versus 4.0%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.185), patient (92.9% versus 94.1% versus 92.1%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.854), and death-censored graft (87.1% versus 90.2% versus 85.1%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.498) survivals. Using a sensitive analysis, the trajectories of estimated glomerular filtration rate were comparable in the intention-to-treat (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.145) and per protocol (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.354) populations. There were no differences in study drug discontinuation rate (22.4% versus 30.4% versus 17.8%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.103).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.<\/jats:title>\n                    <jats:p>In summary, this analysis in a cohort of de novo low\/moderate immunologic risk kidney transplant recipients suggests that the use of a single 3\u2009mg\/kg rabbit antithymocyte globulin dose followed by EVR combined with reduced tacrolimus concentrations was associated with similar efficacy and renal function compared with the standard of care immunosuppressive regimen.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/tp.0000000000003714","type":"journal-article","created":{"date-parts":[[2021,3,3]],"date-time":"2021-03-03T04:31:45Z","timestamp":1614745905000},"page":"381-390","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Long-term Efficacy and Safety of Everolimus Versus Mycophenolate in Kidney Transplant Recipients Receiving Tacrolimus"],"prefix":"10.1097","volume":"106","author":[{"given":"Klaus","family":"Nunes Ficher","sequence":"first","affiliation":[{"name":"Nephrology Division, Hospital do Rim, Universidade Federal de S\u00e3o Paulo, S\u00e3o Paulo, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin","family":"Dreige","sequence":"additional","affiliation":[{"name":"Nephrology Division, Hospital do Rim, Universidade Federal de S\u00e3o Paulo, S\u00e3o Paulo, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo Ricardo","family":"Gessolo Lins","sequence":"additional","affiliation":[{"name":"Nephrology Division, Hospital do Rim, Universidade Federal de S\u00e3o Paulo, S\u00e3o Paulo, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Nicolau Ferreira","sequence":"additional","affiliation":[{"name":"Nephrology Division, Hospital do Rim, Universidade Federal de S\u00e3o Paulo, S\u00e3o Paulo, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Toniato de Rezende Freschi","sequence":"additional","affiliation":[{"name":"Nephrology Division, Hospital do Rim, Universidade Federal de S\u00e3o Paulo, S\u00e3o Paulo, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamilla","family":"Linhares","sequence":"additional","affiliation":[{"name":"Nephrology Division, Hospital do Rim, Universidade Federal de S\u00e3o Paulo, S\u00e3o Paulo, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suelen","family":"Stopa Martins","sequence":"additional","affiliation":[{"name":"Nephrology Division, Hospital do Rim, Universidade Federal de S\u00e3o Paulo, S\u00e3o Paulo, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana","family":"Custodio","sequence":"additional","affiliation":[{"name":"Nephrology Division, Hospital do Rim, Universidade Federal de S\u00e3o Paulo, S\u00e3o Paulo, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Cristelli","sequence":"additional","affiliation":[{"name":"Nephrology Division, Hospital do Rim, Universidade Federal de S\u00e3o Paulo, S\u00e3o Paulo, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laila","family":"Viana","sequence":"additional","affiliation":[{"name":"Nephrology Division, Hospital do Rim, Universidade Federal de S\u00e3o Paulo, S\u00e3o Paulo, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Wagner Santos","sequence":"additional","affiliation":[{"name":"Infectious Diseases Division, Hospital do Rim, Universidade Federal de S\u00e3o Paulo, S\u00e3o Paulo, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"de Marco","sequence":"additional","affiliation":[{"name":"Immunogenetics Institute, Associa\u00e7\u00e3o Fundo de Incentivo \u00e0 Pesquisa, S\u00e3o Paulo, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Gerbase-DeLima","sequence":"additional","affiliation":[{"name":"Immunogenetics Institute, Associa\u00e7\u00e3o Fundo de Incentivo \u00e0 Pesquisa, S\u00e3o Paulo, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrique","family":"Proen\u00e7a","sequence":"additional","affiliation":[{"name":"Pathology Division, Hospital do Rim, Universidade Federal de S\u00e3o Paulo, S\u00e3o Paulo, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilson","family":"Aguiar","sequence":"additional","affiliation":[{"name":"Urology Division, Hospital do Rim, Universidade Federal de S\u00e3o Paulo, S\u00e3o Paulo, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Nephrology Division, Hospital do Rim, Universidade Federal de S\u00e3o Paulo, S\u00e3o Paulo, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Rosso Felipe","sequence":"additional","affiliation":[{"name":"Nephrology Division, Hospital do Rim, Universidade Federal de S\u00e3o Paulo, S\u00e3o Paulo, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Medina Pestana","sequence":"additional","affiliation":[{"name":"Nephrology Division, Hospital do Rim, Universidade Federal de S\u00e3o Paulo, S\u00e3o Paulo, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helio","family":"Tedesco Silva","sequence":"additional","affiliation":[{"name":"Nephrology Division, Hospital do Rim, Universidade Federal de S\u00e3o Paulo, S\u00e3o Paulo, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,2,22]]},"reference":[{"issue":"Suppl 3","key":"R1-20250607","first-page":"S1","article-title":"KDIGO clinical practice guideline for the care of kidney transplant recipients.","volume":"9","year":"2009","journal-title":"Am J Transplant"},{"key":"R2-20250607","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/ki.2009.377","article-title":"KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary.","volume":"77","author":"Kasiske","year":"2010","journal-title":"Kidney Int"},{"key":"R3-20250607","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/ajt.14124","article-title":".","volume":"17 Suppl 1(Suppl 1)","author":"Hart","year":"2017","journal-title":"Am J Transplant"},{"key":"R4-20250607","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1056\/NEJMoa067411","article-title":"Reduced exposure to calcineurin inhibitors in renal transplantation.","volume":"357","author":"Ekberg","year":"2007","journal-title":"N Engl J Med"},{"key":"R5-20250607","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1111\/j.1600-6143.2009.02726.x","article-title":"Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation.","volume":"9","author":"Ekberg","year":"2009","journal-title":"Am J Transplant"},{"key":"R6-20250607","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.trre.2019.07.001","article-title":"Evidence-based practice: guidance for using everolimus in combination with low-exposure calcineurin inhibitors as initial immunosuppression in kidney transplant patients.","volume":"33","author":"Pascual","year":"2019","journal-title":"Transplant Rev (Orlando)"},{"key":"R7-20250607","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1097\/TP.0000000000002291","article-title":"Belatacept in solid organ transplant: review of current literature across transplant types.","volume":"102","author":"Perez","year":"2018","journal-title":"Transplantation"},{"key":"R8-20250607","doi-asserted-by":"crossref","first-page":"205","DOI":"10.5935\/0101-2800.20170035","article-title":"Belatacept in kidney transplantation\u2014past and future perspectives.","volume":"39","author":"Siddiqui","year":"2017","journal-title":"J Bras Nefrol"},{"key":"R9-20250607","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1600-6143.2009.03005.x","article-title":"A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).","volume":"10","author":"Vincenti","year":"2010","journal-title":"Am J Transplant"},{"key":"R10-20250607","first-page":"CD010699","article-title":"Belatacept for kidney transplant recipients.","volume":"2014","author":"Masson","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"R11-20250607","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/01.TP.0000164352.65613.24","article-title":"Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study.","volume":"80","author":"Lorber","year":"2005","journal-title":"Transplantation"},{"key":"R12-20250607","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1681\/ASN.2018010009","article-title":"Everolimus with reduced calcineurin inhibitor exposure in renal transplantation.","volume":"29","author":"Pascual","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"R13-20250607","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1111\/ajt.15480","article-title":"Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study.","volume":"19","author":"Berger","year":"2019","journal-title":"Am J Transplant"},{"key":"R14-20250607","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1097\/TP.0000000000002626","article-title":"Safety of everolimus with reduced calcineurin inhibitor exposure in de novo kidney transplants: an analysis from the randomized TRANSFORM study.","volume":"103","author":"Tedesco-Silva","year":"2019","journal-title":"Transplantation"},{"key":"R15-20250607","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/TP.0000000000000869","article-title":"The influence of immunosuppressive agents on the risk of de novo donor-specific HLA antibody production in solid organ transplant recipients.","volume":"100","author":"O\u2019Leary","year":"2016","journal-title":"Transplantation"},{"key":"R16-20250607","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1111\/ctr.12418","article-title":"Evolution of donor-specific antibodies (DSA) and incidence of de novo DSA in solid organ transplant recipients after switch to everolimus alone or associated with low dose of calcineurin inhibitors.","volume":"28","author":"Perbos","year":"2014","journal-title":"Clin Transplant"},{"key":"R17-20250607","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1093\/ndt\/gfx075","article-title":"Everolimus with cyclosporine withdrawal or low-exposure cyclosporine in kidney transplantation from Month 3: a multicentre, randomized trial.","volume":"32","author":"Budde","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"R18-20250607","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1111\/j.1600-6143.2011.03961.x","article-title":"Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation.","volume":"12","author":"Liefeldt","year":"2012","journal-title":"Am J Transplant"},{"key":"R19-20250607","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.nefro.2016.11.007","article-title":"Recommendations for the use of everolimus in de novo kidney transplantation: false beliefs, myths and realities.","volume":"37","author":"Pascual","year":"2017","journal-title":"Nefrologia"},{"key":"R20-20250607","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1111\/ajt.13327","article-title":"Reduced incidence of cytomegalovirus infection in kidney transplant recipients receiving everolimus and reduced tacrolimus doses.","volume":"15","author":"Tedesco-Silva","year":"2015","journal-title":"Am J Transplant"},{"key":"R21-20250607","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1159\/000475888","article-title":"Donor-specific anti-human leukocyte antigens antibodies, acute rejection, renal function, and histology in kidney transplant recipients receiving tacrolimus and everolimus.","volume":"45","author":"Ferreira","year":"2017","journal-title":"Am J Nephrol"},{"key":"R22-20250607","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1373\/clinchem.2006.077180","article-title":"Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values.","volume":"53","author":"Levey","year":"2007","journal-title":"Clin Chem"},{"key":"R23-20250607","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/TP.0000000000002865","article-title":"Handling of missing data.","volume":"104","author":"Budhiraja","year":"2020","journal-title":"Transplantation"},{"key":"R24-20250607","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1111\/ajt.14090","article-title":"Efficacy and safety of everolimus plus low-dose tacrolimus versus mycophenolate mofetil plus standard-dose tacrolimus in de novo renal transplant recipients: 12-month data.","volume":"17","author":"Qazi","year":"2017","journal-title":"Am J Transplant"},{"key":"R25-20250607","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.kint.2019.01.041","article-title":"An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.","volume":"96","author":"Sommerer","year":"2019","journal-title":"Kidney Int"},{"key":"R26-20250607","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1097\/01.TP.0000081042.67285.91","article-title":"A prospective, randomized, clinical trial of intraoperative versus postoperative Thymoglobulin in adult cadaveric renal transplant recipients.","volume":"76","author":"Goggins","year":"2003","journal-title":"Transplantation"},{"key":"R27-20250607","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1097\/01.tp.0000200305.48244.a6","article-title":"In vivo visualization of the effect of polyclonal antithymocyte globulins on the microcirculation after ischemia\/reperfusion in a primate model.","volume":"81","author":"Chappell","year":"2006","journal-title":"Transplantation"},{"key":"R28-20250607","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ejphar.2012.05.001","article-title":"Mycophenolate mofetil inhibits macrophage infiltration and kidney fibrosis in long-term ischemia-reperfusion injury.","volume":"688","author":"Jiang","year":"2012","journal-title":"Eur J Pharmacol"},{"key":"R29-20250607","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/1440-1681.12687","article-title":"Mycophenolate mofetil improves renal haemodynamics, microvascular oxygenation, and inflammation in a rat model of supra-renal aortic clamping-mediated renal ischaemia reperfusion injury.","volume":"44","author":"Ergin","year":"2017","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"R30-20250607","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1038\/sj.ki.5001893","article-title":"The role of heme oxygenase 1 in rapamycin-induced renal dysfunction after ischemia and reperfusion injury.","volume":"70","author":"Gon\u00e7alves","year":"2006","journal-title":"Kidney Int"},{"key":"R31-20250607","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1097\/01.TP.0000095897.38634.30","article-title":"Sirolimus delays recovery of rat kidney transplants after ischemia-reperfusion injury.","volume":"76","author":"Fuller","year":"2003","journal-title":"Transplantation"},{"key":"R32-20250607","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1681\/ASN.2007111202","article-title":"Sirolimus is associated with new-onset diabetes in kidney transplant recipients.","volume":"19","author":"Johnston","year":"2008","journal-title":"J Am Soc Nephrol"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000003714","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T12:10:10Z","timestamp":1749298210000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000003714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,22]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000003714","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2,22]]}}}